Skip to main content
SpringerLink
Log in

An Introduction to „Recent Trends in the Biotechnology Industry: Development and Manufacturing of Recombinant Antibodies and Proteins“

  • Chapter
  • First Online:
New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins

Part of the book series: Advances in Biochemical Engineering/Biotechnology ((ABE,volume 165))

Abstract

The production of the first therapeutic proteins in the early 1980s heralded the launch of the biopharmaceuticals industry. The number of approved products has grown year on year over the past three decades to now represent a significant share of the entire pharmaceuticals market. More than 200 therapeutic proteins have been approved, approximately a quarter of which are represented by monoclonal antibodies and their derivatives. In 2016, the list of the top 15 best-selling drugs included more than eight biologics and in 2020 the trend will continue, with more than 50% of the top 20 best-selling drugs predicted to be biologics. From 1986 to 2014 several first-in-class, advance-in-class, and breakthrough designated therapeutic options were approved, with advanced therapies such as immuno-oncology and cell-based therapies being approved for several indications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Reichert JM (2001) Monoclonal antibodies in the clinic. Nat Biotechnol 19:819–822

    Article  CAS  PubMed  Google Scholar 

  2. Reichert JM, Pavolu A (2004) Monoclonal antibodies market. Nat Rev Drug Discov 3:383–384

    Article  CAS  PubMed  Google Scholar 

  3. Drapeau M, Sullivan F, Moniz Carpenter J (2007) Special report: blockbuster then and now–trends for billion-dollar drugs. Spectr Ther Markets Emerg Technol 12:1–39

    Google Scholar 

  4. Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev 8:959–968

    CAS  Google Scholar 

  5. Doig AR, Ecker DM, Ransohoff TC (2015) Monoclonal antibody targets and indications. Am Pharm Rev 15:177490

    Google Scholar 

  6. Ecker DM, Dana Jones S, Levine HL (2015) The therapeutic monoclonal antibody market. MAbs 7:9–14

    Article  CAS  PubMed  Google Scholar 

  7. Choi JH, Lee SY (2004) Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 64(5):625–635

    Article  CAS  PubMed  Google Scholar 

  8. Baneyx F, Mujacic M (2004) Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 22(11):1399–1408

    Article  CAS  PubMed  Google Scholar 

  9. Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398

    Article  CAS  PubMed  Google Scholar 

  10. Sethuramann N, Stadheim TA (2006) Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 17(4):341–346

    Article  Google Scholar 

  11. Heath C, Kiss R (2007) Cell culture process development: advances in process engineering. Biotechnol Prog 23:46–51

    Article  CAS  PubMed  Google Scholar 

  12. Su WW (2003) Bioreactors, perfusion. Encyclopedia of cell technology. Wiley, New York, pp 978–993

    Google Scholar 

  13. Shukla A, Thömmes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28:253–261

    Article  CAS  PubMed  Google Scholar 

  14. Kompala D, Ozturk S (2006) Optimization of high density perfusion bioreactors. In: Oztuk S, Hu W-S (eds) Cell culture technology for pharmaceutical and cellular therapies. Taylor and Francis, New York, pp 349–416

    Google Scholar 

  15. Voisard D, Meuwly F, Ruffieux PA, Baer G, Kadouri A (2003) Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng 82(7):751–765

    Article  CAS  PubMed  Google Scholar 

  16. Ryll T, Dutina G, Reyes A, Gunson J, Krummen L, Etcheverry T (2000) Performance of small scale CHO perfusion cultures using an acoustic cell filtration device for cell retention: characterization of separation efficiency and impact of perfusion on product quality. Biotechnol Bioeng 69(4):440–449

    Article  CAS  PubMed  Google Scholar 

  17. Woodside SM, Boweb BD, Piret JM (1998) Mammalian cell retention devices for stirred perfusion bioreactors. Cytotechnology 28:163–175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Castillo RC, Medrohno RA (2004) Cell retention devices for suspended-cell perfusion cultures. In: Scheper T (ed) Adv Biochem Eng Biotechnol 74:129–169

    Google Scholar 

  19. Griffiths JB (1992) Animal cell culture processes—batch or continuous? J Biotechnol 22:21–30

    Article  CAS  PubMed  Google Scholar 

  20. Wang Z, Tan W, Poptic EJ, Belovich J. Feasibility of using a small-scale perfusion bioreactor with a novel cell retention device to inoculate a large-scale bioreactor. In: Conference presentation at the American Chemical Society national meeting, San Francisco, CA

    Google Scholar 

  21. Chu L, Robinson DK (2001) Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 12(2):180–187

    Article  CAS  PubMed  Google Scholar 

  22. Gagnon P (2012) Technology trends in antibody purification. J Chromatogr A 1221:57–70

    Article  CAS  PubMed  Google Scholar 

  23. Jungbauer A (2013) Continuous downstream processing of biopharmaceuticals. Trends Biotechnol 31:479–492

    Article  CAS  PubMed  Google Scholar 

  24. Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345–352

    Article  CAS  PubMed  Google Scholar 

  25. Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. Int Rev Immunol 13(1):65–93

    Article  CAS  PubMed  Google Scholar 

  26. Lalonde ME, Durocher Y (2017) Therapeutic glycoprotein production in mammalian cells. J Biotechnol 251:128–140

    Article  CAS  PubMed  Google Scholar 

  27. Gebauer M, Skerra A (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13(3):245–255

    Article  CAS  PubMed  Google Scholar 

  28. Mullard A (2013) Maturing antibody–drug conjugate pipeline hits 30. Nat Rev Drug Discov 12(5):329–332

    Article  CAS  PubMed  Google Scholar 

  29. Allahyari H, Heidari S, Ghamgosha M, Saffarian P, Amani J (2017) Immunotoxin: a new tool for cancer therapy. Tumour Biol 39(2):1–11, 1010428317692226

    Google Scholar 

  30. Allied Market Research (2014) World biosimilars/follow-on-biologics market—opportunities and forecasts, 2013–2020. Allied Market Research, Portland

    Google Scholar 

  31. Gottschalk U, Brorson K, Shukla AA (2012) The need for innovation in biomanufacturing. Nat Biotechnol 30(6):489–492

    Article  CAS  PubMed  Google Scholar 

  32. Gutierrez JM, Lewis NE (2015) Optimizing eukaryotic cell hosts for protein production through systems biotechnology and genome-scale modeling. Biotechnol J 10(7):939–949

    Article  CAS  PubMed  Google Scholar 

  33. Shukla AA, Gottschalk U (2013) Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol 31(3):147–154

    Article  CAS  PubMed  Google Scholar 

  34. Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM (2010) Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 44(1):41–47

    Article  CAS  PubMed  Google Scholar 

  35. Buyel JF, Twyman RM, Fischer R (2017) Very-large-scale production of antibodies in plants: the biologization of manufacturing. Biotechnol Adv 35:458–665

    Article  CAS  PubMed  Google Scholar 

  36. Rathore AS (2016) Quality by design (QbD)-based process development for purification of a biotherapeutic. Trends Biotechnol 34(5):358–370

    Article  CAS  PubMed  Google Scholar 

  37. Pohlscheidt M, Jacobs M, Wolf S, Thiele J, Jockwer A, Gabelsberger J, Jenzsch M, Tebbe H, Burg J (2013) Optimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactors. Biotechnol Prog 29(1):222–229

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biogen International GmbH, International Manufacturing, Zug, Switzerland

    Michael Pohlscheidt, Robert Kiss & Uwe Gottschalk

Authors
  1. Michael Pohlscheidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Kiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uwe Gottschalk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Pohlscheidt .

Editor information

Editors and Affiliations

  1. Sutro Biopharma Inc., San Francisco, CA, USA

    Bob Kiss

  2. Lonza, Basel, Switzerland

    Uwe Gottschalk

  3. Solothurn Manufacturing Facility, Biogen International GmbH, Luterbach, Switzerland

    Michael Pohlscheidt

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pohlscheidt, M., Kiss, R., Gottschalk, U. (2018). An Introduction to „Recent Trends in the Biotechnology Industry: Development and Manufacturing of Recombinant Antibodies and Proteins“. In: Kiss, B., Gottschalk, U., Pohlscheidt, M. (eds) New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins. Advances in Biochemical Engineering/Biotechnology, vol 165. Springer, Cham. https://doi.org/10.1007/10_2017_39

Download citation

Publish with us

Policies and ethics

Search

Navigation